ProlX Pharmaceuticals Corp. Initiates Phase 1B Trial In Gastrointestinal Cancer For Novel Thioredoxin Inhibitor PX-12

TUCSON, Ariz.--(BUSINESS WIRE)--Jan. 20, 2006--ProlX Pharmaceuticals Corp. announced today that it has enrolled the first patient in a Phase IB clinical trial to study a novel thioredoxin inhibitor, PX-12, in patients with advanced gastrointestinal cancers. This trial is designed to explore a new schedule of delivery with PX-12 given as a 24-hour infusion every two weeks, evaluating its safety, pharmacokinetic profile, and antitumor activity. The study will be conducted by Dr. Tomislav Dragovich at the Arizona Cancer Center in Tucson, Ariz.

MORE ON THIS TOPIC